Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ495497-0,50
KB5615640,90
PKN68,4668,480,12
Msft-1,32
Nokia3,80153,8595-2,87
IBM-0,12
Daimler AG37,0737,095-2,46
PFE-0,41
04.06.2020 23:26:40
Indexy online
AD Index online
select
AD Index online
 

  • 04.06.2020 21:59:44
Novartis AG Depository Receipt (NVS, NY Consolidated)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
85,09 -0,72 -0,62 1 747 076
After-hours04.06.2020 23:17:17
Poslední obchod Nákup / Prodej Změna (%) Změna (USD)
85,15 - - -0,68 -0,58
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 04.06.2020
Popis společnosti
Obecné informace
Název společnostiNovartis AG (ADR)
TickerNVS
Kmenové akcie:ADR
RICNVS
ISINUS66987V1098
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky31.12.2019
Počet zaměstnanců k 31.12.2019 103 914
Akcie v oběhu k 31.12.20192 265 008 488
Počet akcionářů k 31.12.2019 161 111
MěnaUSD
Kontaktní informace
UliceLichtstrasse 35
MěstoBASEL
PSČ4056
ZeměSwitzerland
Kontatní osoba 
Funkce kontaktní osoby 
Telefon41 613 241 111
Fax41613247826

Business Summary: Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2019, Novartis AG (ADR) revenues increased 6% to $48.62B. Net income before extraordinary items decreased 44% to $7.14B. Revenues reflect Innovative Medicines segment increase of 8% to $37.71B, United States segment increase of 11% to $16.28B, Other Foreign- segment increase of 4% to $21.1B, Germany segment increase of 4% to $4.12B. Net income was offset by Sandoz segment income decrease of 59% to $551M.
Odvětvová klasifikace
TRBC2012Pharmaceuticals - NEC
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYMajor Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSMedicinal and Botanical Manufacturing
NAICSSurgical and Medical Instrument Manufacturing
NAICSOphthalmic Goods Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSOffices of Other Holding Companies
SICPharmaceutical Preparations
SICBiological Prod's Not Diagnostic
SICMedicinals And Botanicals
SICSurgical And Medical Instruments
SICOphthalmic Goods
SICCommercial Physical Research
SICHolding Companies, Nec



  • Poslední aktualizace: 04.06.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Member of the Executive CommitteeVasant Narasimhan4401.02.201801.02.2016
Chief Financial Officer, Member of the Executive CommitteeHarry Kirsch5501.05.201301.05.2013
Chief People & Organization Officer, Member of the Executive CommitteeSteven Baert4626.02.201426.02.2014
Global Head of Novartis Technical Operations, Member of the Executive CommitteeSteffen Lang5301.04.201801.04.2018
Chief Ethics, Risk and Compliance Officer, Member of the Executive CommitteeKlaus Moosmayer5201.12.201801.12.2018
Group General Counsel, Member of the Executive CommitteeShannon Klinger4901.06.201801.04.2018
Chief Digital Officer, Member of the Executive CommitteeBertrand Bodson4501.04.201801.01.2018
President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive CommitteeJames Bradner4801.03.201601.03.2016
Chief Executive Officer of Sandoz, Member of the Executive CommitteeRichard Saynor5315.07.201915.07.2019
CEO Novartis Oncology, Member of the Executive CommitteeSusanne Schaffert5301.01.201901.01.2019